Clinical Trial Update: Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating safety of donepezil hydrochloride in children with Down syndrome over up to one year; the study was terminated with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome

Drugs mentioned

• Donepezil hydrochloride (Donepezil hydrochloride)

Snippet

Sponsor: Eisai Inc. | Conditions: Down Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2021-03-29